HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment.
The clearance followed a successful appeal of a previous not substantially equivalent determination, the company said in a Dec. 9 news release. The system uses a three-axis signal capture method to generate a 12-lead ECG without traditional electrode cables.
HeartBeam plans a limited commercial launch in early 2026, focusing on concierge and preventive cardiology practices. The initial rollout will support real-world testing and inform broader distribution.
The company’s future initiatives include a wearable 12-lead ECG patch and an AI-enabled platform trained on longitudinal patient data. HeartBeam said the clearance supports its efforts to expand access to diagnostic ECG data outside traditional care settings.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
